GB201220899D0 - CD44v6-derived pegylated peptides - Google Patents
CD44v6-derived pegylated peptidesInfo
- Publication number
- GB201220899D0 GB201220899D0 GBGB1220899.7A GB201220899A GB201220899D0 GB 201220899 D0 GB201220899 D0 GB 201220899D0 GB 201220899 A GB201220899 A GB 201220899A GB 201220899 D0 GB201220899 D0 GB 201220899D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cd44v6
- derived
- pegylated peptides
- pegylated
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010058905 CD44v6 antigen Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220899.7A GB201220899D0 (en) | 2012-11-21 | 2012-11-21 | CD44v6-derived pegylated peptides |
| PCT/EP2013/074353 WO2014079914A1 (en) | 2012-11-21 | 2013-11-21 | Cd44v6-derived pegylated peptides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220899.7A GB201220899D0 (en) | 2012-11-21 | 2012-11-21 | CD44v6-derived pegylated peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201220899D0 true GB201220899D0 (en) | 2013-01-02 |
Family
ID=47521469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1220899.7A Ceased GB201220899D0 (en) | 2012-11-21 | 2012-11-21 | CD44v6-derived pegylated peptides |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201220899D0 (en) |
| WO (1) | WO2014079914A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015021993A1 (en) * | 2013-08-13 | 2015-02-19 | Ibcc Holding As | Pharmacologically active modified sb101 molecules and uses thereof |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| CN113444139B (en) * | 2020-03-25 | 2023-04-21 | 中国科学院大学 | Enhancement of synthesis and enzymatic hydrolysis of pegylated D-amino acid-containing polypeptides |
| EP4464714A1 (en) | 2023-05-19 | 2024-11-20 | Karlsruher Institut für Technologie | Screening method for cell-repelling peptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| EP1391213A1 (en) * | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1647556B1 (en) * | 2004-10-14 | 2010-05-19 | Karlsruher Institut für Technologie | Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors |
| US7842467B1 (en) * | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| EP1770099A1 (en) * | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| ATE523204T1 (en) * | 2009-02-16 | 2011-09-15 | Karlsruher Inst Technologie | CD44V6 PEPTIDES AS BACTERIAL INFECTION INHIBITORS |
| EP2266593A1 (en) * | 2009-06-24 | 2010-12-29 | Karlsruher Institut für Technologie | Use of CD44v6 in the treatment of ophthalmic diseases |
| EP2467491A4 (en) * | 2009-08-21 | 2014-04-02 | Sinai School Medicine | METHODS OF USING CD44 FUSION PROTEINS TO TREAT CANCER |
| CA2830792A1 (en) * | 2011-03-24 | 2012-09-27 | Neurim Pharmaceuticals (1991) Ltd. | Neuroprotective peptides |
-
2012
- 2012-11-21 GB GBGB1220899.7A patent/GB201220899D0/en not_active Ceased
-
2013
- 2013-11-21 WO PCT/EP2013/074353 patent/WO2014079914A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014079914A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291571A (en) | Cx3cr1-binding polypeptides | |
| EP2857033A4 (en) | Skin-permeating peptide | |
| GB201220474D0 (en) | Polypeptides | |
| GB201218813D0 (en) | Antimicrobial peptides | |
| GB201111183D0 (en) | Peptide | |
| GB201418188D0 (en) | Peptide arrays | |
| GB201115910D0 (en) | Peptides | |
| PT2809342T (en) | Bifunctional peptide | |
| ZA201503127B (en) | Peptides | |
| HUE055593T2 (en) | Improved cd31 peptides | |
| GB201200555D0 (en) | Peptide | |
| GB201220899D0 (en) | CD44v6-derived pegylated peptides | |
| GB201204868D0 (en) | Peptides | |
| SG11201404180RA (en) | Cho-gmt recombinant protein expression | |
| GB201223114D0 (en) | Novel peptide | |
| PT2891663T (en) | Psf1-derived peptides | |
| IL235840A0 (en) | Alternaria peptides | |
| GB201213672D0 (en) | Protein | |
| GB201220328D0 (en) | Peptides | |
| GB201211740D0 (en) | Peptides | |
| GB201207895D0 (en) | Peptides | |
| GB201200509D0 (en) | Peptides | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201200624D0 (en) | Peptide | |
| GB201200623D0 (en) | Peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |